Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
The Sickle Cell Infusion Center at Johns HopkinsThe Sickle Cell Center for Adults is ded...
-
Megan Davis, MDDr. Megan Davis received her medical deg...
-
NYC Health + HospitalsNYC Health + Hospitals are the largest p...
-
Theodore Wun, MD, FACPDr. Wun graduated from the Albany Medica...
-
Sickle Cell Patients Endure Discrimination, Poor Care And Shortened LivesFor more than a year, NeDina Brocks-Capl...
-
GlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics, Inc. (NASDAQ: GLYC), a cl...
-
Gene-Edited ‘Supercells’ Make Progress In Fight Against Sickle Cell DiseaseDoctors are reporting the first evidence...
